6533b824fe1ef96bd12816ed

RESEARCH PRODUCT

An overview on anti-tubulin agents for the treatment of lymphoma patients

Paola BarrajaAnastasios StathisFrancesco BertoniMarilia Barreca

subject

0301 basic medicineVinca alkaloidsLymphomaMitosisAntineoplastic AgentsApoptosismacromolecular substancesMicrotubulesAntibody drug conjugatesTaxanes03 medical and health sciences0302 clinical medicineTubulinMicrotubulemedicineAnimalsHumansMaytansinePharmacology (medical)MetaphaseMitosisAnaphasePharmacologybiologybusiness.industryCancerCombination chemotherapymedicine.diseaseTubulin ModulatorsLymphoma030104 developmental biologyTubulinEpothilones030220 oncology & carcinogenesisbiology.proteinCancer researchDolastatinsbusiness

description

Anti-tubulin agents constitute a large class of compounds with broad activity both in solid tumors and hematologic malignancies, due to the interference with microtubule dynamics. Since microtubules play crucial roles in the regulation of the mitotic spindles, the interference with their function usually leads to a block in cell division with arrest at the metaphase/anaphase junction of mitosis, followed to apoptosis. This explains the reason why tubulin-binding agents (TBAs) proved to be extremely active in patients with cancer. Several anti-tubulin agents are indicated in the treatment of patients with lymphomas both alone and in combination chemotherapy regimens. The article reviews the literature on classic and more recent anti-tubulin agents, providing an insight into their mechanisms of action and their use in the treatment of lymphoma.

https://doi.org/10.1016/j.pharmthera.2020.107552